リンパ球活性化遺伝子 3 (LAG-3) は、1990 年に発見されたタンパク質で、NK 細胞、活性化 T 細胞、B 細胞、形質細胞様樹状細胞の細胞表面に発現することがわかっています。LAG-3 は免疫チェックポイントであり、がん、慢性感染症、自己免疫疾患の治療薬や治療法を開発するための標的と見なされています。何十年にもわたる研究活動にもかかわらず、LAG-3、特にその作用機序に関する知識の多くは、まだ発見されていないと考えられています。LAG-3 は、複数の疾患を管理するための治療標的としての可能性を秘めているため、効果的な治療戦略を開発するためには、タンパク質とその機能を徹底的に調査することが不可欠です。
目次
1. Introduction to LAG-3 Inhibitor
1.1 Overview Of LAG-3 inhibitors
1.2 Mechanism of Action
1.3 LAG-3 Targeted Therapy Approaches
1.3.1 Targeting LAG-3 With Fusion Proteins
1.3.2 Targeting LAG-3 With Monoclonal Antibodies
1.3.3 Targeting LAG-3 With Bispecific Antibodies
2. LAG-3 Targeted Therapy In By Indication
2.1 Cancer
2.2 Viral Infections
2.3 Autoimmune Diseases
2.4 Parkinson Disease
3. Opdualag - 1st Approved LAG-3 Inhibitor Clinical Insight
4. Opdualag - 1st Approved LAG-3 Inhibitor Commercial Insight
4.1 Overview and Patent Analysis
4.2 Pricing and Dosage Analysis
4.3 Sales Analysis
5. Global LAG-3 Inhibitor Market
5.1 Current Market Overview
5.2 Market Opportunity Assessment
6. Global LAG-3 Inhibitor Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
7. Global LAG-3 Inhibitor Clinical Trials Insight 2023 -2028
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
8. Global LAG-3 Inhibitor Market Dynamics
8.1 Market Drivers and Opportunities
8.2 Commercialization Challenges
9. Global LAG-3 Inhibitor Market Future Outlook
10. Competitive Landscape
10.1 Abeome Corporation
10.2 ABL Bio
10.3 Agenus
10.4 Akeso Biopharma
10.5 AnaptysBio
10.6 Bristol-Myers Squibb
10.7 Cancer Research UK
10.8 F-star Therapeutics
10.9 Immutep
10.10 Incyte Corporation
10.11 Innovent Biologics
10.12 Ligand Pharmaceuticals
10.13 Merck
10.14 Shanghai Fosun Pharmaceutical
10.15 Y-Biologics
List of Figures & Tables
Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Inhibitor - Mechanism of Action
Figure 1-3: Binding Efficacy of Bispecific Antibodies
Figure 2-1: LAG-3 Signaling in Cancer Cell
Figure 2-2: LAG-3 on T Cells During HIV Infection
Figure 2-3: LAG-3 Associated Autoimmune Diseases
Figure 2-4: Implication of LAG-3 in PD Progression
Figure 2-5: Biomarker Potential of LAG-3 in Parkinson Disease
Figure 4-1: Opdualag - Years Of Approval
Figure 4-2: Opdualag - FDA Orphan and Priority Review Designation Year
Figure 4-3: Neo ReNi II Study - Estimated Starting and Ending Years
Figure 4-4: RELATIVITY-127 Study - Estimated Starting and Ending Years
Figure 4-5: US - Price Of 20ml Vial Of Opdualag (US$), February, 2023
Figure 4-6: US/Global - Opdualag Quarterly Sales (US$ Million), 2022
Figure 5-1: Global - Cancer Immunotherapy Market Size (US$ Billion), 2023 - 2028
Figure 5-2: Global - LAG-3 Inhibitor Market Opportunity by 1% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-3: Global - LAG-3 Inhibitor Market Opportunity by 2% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-4: Global - LAG-3 Inhibitor Market Opportunity by 3% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-5: Global - LAG-3 Inhibitor Market Opportunity by 4% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-6: Global - LAG-3 Inhibitor Market Opportunity by 5% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-7: Global - LAG-3 Inhibitor Market Opportunity by 6% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-8: Global - LAG-3 Inhibitor Market Opportunity by 7% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-9: Global - LAG-3 Inhibitor Market Opportunity by 8% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-10: Global - LAG-3 Inhibitor Market Opportunity by 9% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-11: Global - LAG-3 Inhibitor Market Opportunity by 10% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 6-1: Global - LAG 3 Inhibitor Clinical Trials By Company, 2023 till 2028
Figure 6-2: Global - LAG 3 Inhibitor Clinical Trials By Country, 2023 till 2028
Figure 6-3: Global - LAG 3 Inhibitor Clinical Trials By Indication, 2023 till 2028
Figure 6-4: Global - LAG 3 Inhibitors Clinical Trials By Patient Segment, 2023 till 2028
Figure 6-5: Global - Number of LAG 3 Inhibitors In Clinical Trials By Phase, 2023 till 2028
Figure 8-1: LAG-3 Inhibitor Market Drivers and Opportunities
Figure 8-2: LAG-3 Inhibitor Market Challenges and Restraints
Table 2-1: Correlation between LAG-3 and TIL in Cancer
Table 2-2: Expression of LAG-3 in different Cancers and its Clinicopathological Condition
Table 4-1: Maximum Infusion Volumes and Concentration Ranges By Patient Group
Table 4-2: Recommended Opdualag Dosage Modifications For Adverse Reactions
Table 10-1: Agenus - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-2: AnaptysBio - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-3: Bristol-Myers Squibb - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-4: F-star - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-5: Immutep - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-6: Incyte Corporation - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-7: Innovent Biologics - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-8: Ligand Pharmaceuticals - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-9: Merck KGaA - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-10: Shanghai Fosun Pharmaceutical - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
